ASTRAZENECA PLC (AZN) Form 6-K — Sep 1, 2026
AstraZeneca completed the previously announced exclusive global license agreement with Dizal Pharmaceutical, acquiring worldwide rights to develop and commercialise Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for lung cancer. Under the deal terms, AstraZeneca will pay Dizal a $600m upfront payment plus up to $900m in additional development, regulatory and sales milestones, with Dizal also earning tiered royalties on global sales. The transaction does not impact AstraZeneca's 2026 financial guidance.
Key figures
- Deal Value Usd
- $600m upfront plus up to $900m in milestone payments (up to $1.5bn total potential)
- Approved markets
- ["US","China"]
- Us launch timing
- Q4 2026 (2nd-line NSCLC indication)
- Royalty structure
- tiered royalties to Dizal on global sales of Zegfrovy
- Upfront payment usd
- 600000000
- Guidance impact 2026
- none
- Breakthrough designations
- ["US FDA (1st-line)","China CDE (1st-line)"]
- Milestone payments max usd
- 900000000
- Five year overall survival egfr exon20
- as low as 8%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.